Showing 1591-1600 of 1692 results for "".
- Subcutaneous Lecanemab Approved by FDA for Maintenance Dosing in Alzheimer Diseasehttps://practicalneurology.com/news/subcutaneous-lecanemab-approved-by-fda-for-maintenance-dosing-in-alzheimer-disease/2483177/The Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for a subcutaneous formulation of lecanemab called Leqembi IQLIK (lecanemab-irmb; Eisai, Tokyo, Japan; Biogen, Cambridge, MA) for maintenance dosing for the treatment of people with early Alzheimer disease
- Catherine Chu, MD, to Lead Pediatric Neurology at Kennedy Krieger and Johns Hopkinshttps://practicalneurology.com/news/catherine-chu-md-to-lead-pediatric-neurology-at-kennedy-krieger-and-johns-hopkins/2475483/Catherine Chu, MD, MA, MMSc, has been named Vice President of Child Neurology of the Kennedy Krieger Institute and will also serve as Director of the Division of Pediatric Neurology and the John M. Freeman Pediatric Epilepsy Center at Johns Hopkins Children’s Center. According to a statement rele
- Non-Opioid Drug Significantly Reduced Pain After Surgery, Studies Revealhttps://practicalneurology.com/news/non-opioid-drug-significantly-reduced-pain-after-surgery-studies-reveal/2474650/Treatment with MR-107A-02 (meloxicam; Viatris, Pittsburgh, PA), a novel, oral, fast-acting formulation of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, was shown to significantly reduce pain and opioid usage vs placebo in top-line results from 2 phase 3 clinical studies. Additionally
- New Recommendations on Glucocorticoid Treatment for People with Neuromuscular Disordershttps://practicalneurology.com/news/new-guidelines-published-for-glucocorticoid-treatment-for-people-with-neuromuscular-disorders/2474507/A multidisciplinary expert panel has released new consensus-based recommendations on glucocorticoid use for people with neuromuscular disorders, aiming to streamline clinical decisions amid a lack of specific, formal guidelines. Published in Muscle and Nerve, the guidance aims to support safer, m
- Nasal Powder Approved by FDA for Treatment of Adults with Acute Migrainehttps://practicalneurology.com/news/nasal-powder-approved-by-fda-for-treatment-of-adults-with-acute-migraine/2474441/The Food and Drug Administration (FDA) has approved Atzumi (dihydroergotamine [DHE]; Satsuma Pharmaceuticals, Durham, NC) for the treatment of adults with acute migraine with or without aura. Atzumi is a powder formulation designed for intranasal drug delivery via a squeezable device. FDA
- The FDA Approves a Once-Daily Medication for Treating Hyperphagia Caused by Prader-Willi Syndromehttps://practicalneurology.com/news/the-fda-approves-a-once-daily-medication-for-treating-hyperphagia-caused-by-prader-willi-syndrome/2473822/The Food and Drug Administration (FDA) has approved Vykat XR (diazoxide choline [DCCR] extended-release tablets; Soleno, Redwood City, CA) for the treatment of hyperphagia in people with Prader-Willi syndrome (PWS) aged 4 years and older. Vykat XR is an extended-release formulation of DCCR, a cry
- Switching to SC Kesimpta from IVAnti-CD20 Therapies is Safe, Effective Across Diverse Individuals with Relapsing MShttps://practicalneurology.com/news/Switching-SC-Kesimpta-IVAnti-CD20-Therapies-Safe-Effective-Across-Diverse-Individuals-Relapsing-MS/2471739/Study results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 demonstrated that treatment with Kesimpta (ofatumumab; Novartis, Cambridge, MA) maintained efficacy across ethnic and racial groups in individuals with relapsing multiple sclero
- Associations Between NfL Concentrations and Cognitive and Radiologic Outcomes Revealed in Study of Individuals with RMS Treated with Zeposiahttps://practicalneurology.com/news/associations-between-relapsing-ms-treatment-with-zeposia-nfl-concentrations-and-cognitive-and-radiologic-outcomes-revealed-in-1-year-interim-analysis-data/2473801/Research presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 demonstrated that neurofilament light chain (NfL) may be a useful biomarker for both cognitive and radiologic outcomes in early relapsing multiple sclerosis (RMS). The findings resul
- Study Identifies Significant Variations in Pediatric MOGAD Treatmenthttps://practicalneurology.com/news/study-identifies-significant-variations-in-pediatric-mogad-treatment/2473800/The results of a study presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 found significant variations in how neurologists treat pediatric individuals with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Res
- Switching to SC Kesimpta from IV Anti-CD20 Therapies is Safe, Effective Across Diverse Individuals with Relapsing MShttps://practicalneurology.com/news/kesimpta-maintains-efficacy-across-race-and-ethnic-groups-in-relapsing-ms-patients-transitioning-from-intravenous-anti-cd20-therapies/2473797/Study results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 demonstrated that treatment with Kesimpta (ofatumumab; Novartis, Cambridge, MA) maintained efficacy across ethnic and racial groups in individuals with relapsing multiple sclero